TY  - JOUR
AU  - Casasnovas, Rene-Olivier
AU  - Follows, George
AU  - Zijlstra, Josee M
AU  - Vermaat, Joost S P
AU  - Kalakonda, Nagesh
AU  - Choquet, Sylvain
AU  - Neste, Eric Van Den
AU  - Hill, Brian
AU  - Thieblemont, Catherine
AU  - Cavallo, Federica
AU  - la Cruz, Fatima De
AU  - Kuruvilla, John
AU  - Hamad, Nada
AU  - Jaeger, Ulrich
AU  - Caimi, Paolo F
AU  - Gurion, Ronit
AU  - Warzocha, Krzysztof
AU  - Bakhshi, Sameer
AU  - Sancho, Juan-Manuel
AU  - Schuster, Michael
AU  - Egyed, Miklos
AU  - Offner, Fritz
AU  - Vassilakopoulos, Theodoros P
AU  - Samal, Priyanka
AU  - Ku, Matthew
AU  - Ma, Xiwen
AU  - Chamoun, Kamal
AU  - Shah, Jatin
AU  - Canales, Miguel
AU  - Maerevoet, Marie
AU  - Shacham, Sharon
AU  - Kauffman, Michael G
AU  - Goy, Andre
PY  - 2021
DO  - 10.1016/j.clml.2021.07.017
UR  - http://hdl.handle.net/10668/22107
T2  - Clinical lymphoma, myeloma & leukemia
AB  - The SADAL study evaluated oral selinexor in patients with relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL) after at least 2 prior lines of systemic therapy. In this post-hoc analysis, we analyzed the outcomes of the SADAL study by...
LA  - en
KW  - DLBCL subtypes
KW  - De novo and transformed DLBCL
KW  - Relapsed/refractory DLBCL
KW  - Salvage therapy
KW  - Treatment response
KW  - XPO1
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Female
KW  - Humans
KW  - Hydrazines
KW  - Lymphoma, Large B-Cell, Diffuse
KW  - Male
KW  - Middle Aged
KW  - Treatment Outcome
KW  - Triazoles
TI  - Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes.
TY  - research article
VL  - 22
ER  -